Highly portable quantitative screening test for prostate-specific antigen at point of care

Prostate cancer (PCa) is the second most diagnosed cancer among men. Targeted PCa screening may decrease PCa-specific mortality. Prostate-specific antigen (PSA) is the most reliable and widely accepted tumor biomarker for screening and monitoring PCa status. However, in many settings, quantification...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Balaji Srinivasan, David M. Nanus, David Erickson, Saurabh Mehta
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Prostate cancer Screening Point of care POCT Prostate-specific antigen Cancer Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/73b22ced6c0e487ab6c08edf45a1f912
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73b22ced6c0e487ab6c08edf45a1f912
record_format	dspace
spelling	oai:doaj.org-article:73b22ced6c0e487ab6c08edf45a1f9122021-11-22T04:29:47ZHighly portable quantitative screening test for prostate-specific antigen at point of care2590-262810.1016/j.crbiot.2021.11.003https://doaj.org/article/73b22ced6c0e487ab6c08edf45a1f9122021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2590262821000332https://doaj.org/toc/2590-2628Prostate cancer (PCa) is the second most diagnosed cancer among men. Targeted PCa screening may decrease PCa-specific mortality. Prostate-specific antigen (PSA) is the most reliable and widely accepted tumor biomarker for screening and monitoring PCa status. However, in many settings, quantification of serum PSA requires access to centralized laboratories. In this study, we describe a proof-of-concept rapid test combined with a highly portable CubeTM reader for quantification of total PSA from a drop of serum within 20 min. We demonstrated the application of gold nanoshells as a label for lateral flow assay with significant increase in the measured colorimetric signal intensity to achieve five times lower detection limit when compared to the traditionally used 40 nm gold nanosphere labels, without a need for any additional signal amplification steps. We first optimized and evaluated the performance of the assay with commercially available total PSA calibrators. For initial validation with commercially available ACCESS Hybritech PSA calibrator, a detection range of 0.5–150 ng/mL was achieved. We compared the performance of our total PSA test with IMMULITE analyzer for quantification of total PSA in archived human serum samples. On preliminary testing with archived serums samples and comparison with IMMULITE total PSA assay, a correlation of 0.95 (p < .0001) was observed. The highly portable quantitative screening test for PSA described in this study has the potential to make PCa screening more accessible where diagnostic labs and automated immunoassay systems are not available, to reduce therapeutic turnaround time, to streamline clinical care, and to direct patient care for both initial screening and for post-treatment monitoring of patients.Balaji SrinivasanDavid M. NanusDavid EricksonSaurabh MehtaElsevierarticleProstate cancerScreeningPoint of carePOCTProstate-specific antigenCancerBiotechnologyTP248.13-248.65ENCurrent Research in Biotechnology, Vol 3, Iss , Pp 288-299 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Prostate cancer Screening Point of care POCT Prostate-specific antigen Cancer Biotechnology TP248.13-248.65
spellingShingle	Prostate cancer Screening Point of care POCT Prostate-specific antigen Cancer Biotechnology TP248.13-248.65 Balaji Srinivasan David M. Nanus David Erickson Saurabh Mehta Highly portable quantitative screening test for prostate-specific antigen at point of care
description	Prostate cancer (PCa) is the second most diagnosed cancer among men. Targeted PCa screening may decrease PCa-specific mortality. Prostate-specific antigen (PSA) is the most reliable and widely accepted tumor biomarker for screening and monitoring PCa status. However, in many settings, quantification of serum PSA requires access to centralized laboratories. In this study, we describe a proof-of-concept rapid test combined with a highly portable CubeTM reader for quantification of total PSA from a drop of serum within 20 min. We demonstrated the application of gold nanoshells as a label for lateral flow assay with significant increase in the measured colorimetric signal intensity to achieve five times lower detection limit when compared to the traditionally used 40 nm gold nanosphere labels, without a need for any additional signal amplification steps. We first optimized and evaluated the performance of the assay with commercially available total PSA calibrators. For initial validation with commercially available ACCESS Hybritech PSA calibrator, a detection range of 0.5–150 ng/mL was achieved. We compared the performance of our total PSA test with IMMULITE analyzer for quantification of total PSA in archived human serum samples. On preliminary testing with archived serums samples and comparison with IMMULITE total PSA assay, a correlation of 0.95 (p < .0001) was observed. The highly portable quantitative screening test for PSA described in this study has the potential to make PCa screening more accessible where diagnostic labs and automated immunoassay systems are not available, to reduce therapeutic turnaround time, to streamline clinical care, and to direct patient care for both initial screening and for post-treatment monitoring of patients.
format	article
author	Balaji Srinivasan David M. Nanus David Erickson Saurabh Mehta
author_facet	Balaji Srinivasan David M. Nanus David Erickson Saurabh Mehta
author_sort	Balaji Srinivasan
title	Highly portable quantitative screening test for prostate-specific antigen at point of care
title_short	Highly portable quantitative screening test for prostate-specific antigen at point of care
title_full	Highly portable quantitative screening test for prostate-specific antigen at point of care
title_fullStr	Highly portable quantitative screening test for prostate-specific antigen at point of care
title_full_unstemmed	Highly portable quantitative screening test for prostate-specific antigen at point of care
title_sort	highly portable quantitative screening test for prostate-specific antigen at point of care
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/73b22ced6c0e487ab6c08edf45a1f912
work_keys_str_mv	AT balajisrinivasan highlyportablequantitativescreeningtestforprostatespecificantigenatpointofcare AT davidmnanus highlyportablequantitativescreeningtestforprostatespecificantigenatpointofcare AT daviderickson highlyportablequantitativescreeningtestforprostatespecificantigenatpointofcare AT saurabhmehta highlyportablequantitativescreeningtestforprostatespecificantigenatpointofcare
_version_	1718418167818092544

Highly portable quantitative screening test for prostate-specific antigen at point of care

Ejemplares similares